Evaluating Antiangiogenesis Agents in the Clinic

The Eastern Cooperative Oncology Group Portfolio of Clinical Trials

Joseph A. Sparano, Robert Gray, Bruce Giantonio, Peter O'Dwyer, Robert L. Comis

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Recent evidence indicates that treatment with a humanized monoclonal antibody (bevacizumab) directed at vascular endothelial growth factor improves response and survival in metastatic colorectal cancer when added to standard chemotherapy, validating angiogenesis as a therapeutic target. Investigators from the Eastern Cooperative Oncology Group (ECOG) have initiated a number of Phase III studies that will help further define the role of antiangiogenic agents for the treatment of breast, colon, lung, renal, and head and neck cancer, as well as melanoma and myeloma. The agents being evaluated target various biological functions involved in angiogenesis, including vascular endothelial growth factor (bevacizumab), endothelial cell proliferation (thalidomide, IFN-α), and matrix metalloproteinases (marimastat). These clinical trials include correlative laboratory studies aimed at elucidating how these agents may exert their clinical effects. The portfolio of Eastern Cooperative Oncology Group studies will serve to further define the role of this therapeutic strategy for patients with advanced cancer.

Original languageEnglish (US)
Pages (from-to)1206-1211
Number of pages6
JournalClinical Cancer Research
Volume10
Issue number4
DOIs
StatePublished - Feb 15 2004

Fingerprint

Clinical Trials
Vascular Endothelial Growth Factor A
Antibodies, Monoclonal, Humanized
Thalidomide
Angiogenesis Inhibitors
Kidney Neoplasms
Therapeutics
Head and Neck Neoplasms
Matrix Metalloproteinases
Colorectal Neoplasms
Melanoma
Colon
Breast
Endothelial Cells
Research Personnel
Cell Proliferation
Drug Therapy
Lung
Survival
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluating Antiangiogenesis Agents in the Clinic : The Eastern Cooperative Oncology Group Portfolio of Clinical Trials. / Sparano, Joseph A.; Gray, Robert; Giantonio, Bruce; O'Dwyer, Peter; Comis, Robert L.

In: Clinical Cancer Research, Vol. 10, No. 4, 15.02.2004, p. 1206-1211.

Research output: Contribution to journalArticle

Sparano, Joseph A. ; Gray, Robert ; Giantonio, Bruce ; O'Dwyer, Peter ; Comis, Robert L. / Evaluating Antiangiogenesis Agents in the Clinic : The Eastern Cooperative Oncology Group Portfolio of Clinical Trials. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 4. pp. 1206-1211.
@article{80c369bbf70a4f358c912e64153f0ebb,
title = "Evaluating Antiangiogenesis Agents in the Clinic: The Eastern Cooperative Oncology Group Portfolio of Clinical Trials",
abstract = "Recent evidence indicates that treatment with a humanized monoclonal antibody (bevacizumab) directed at vascular endothelial growth factor improves response and survival in metastatic colorectal cancer when added to standard chemotherapy, validating angiogenesis as a therapeutic target. Investigators from the Eastern Cooperative Oncology Group (ECOG) have initiated a number of Phase III studies that will help further define the role of antiangiogenic agents for the treatment of breast, colon, lung, renal, and head and neck cancer, as well as melanoma and myeloma. The agents being evaluated target various biological functions involved in angiogenesis, including vascular endothelial growth factor (bevacizumab), endothelial cell proliferation (thalidomide, IFN-α), and matrix metalloproteinases (marimastat). These clinical trials include correlative laboratory studies aimed at elucidating how these agents may exert their clinical effects. The portfolio of Eastern Cooperative Oncology Group studies will serve to further define the role of this therapeutic strategy for patients with advanced cancer.",
author = "Sparano, {Joseph A.} and Robert Gray and Bruce Giantonio and Peter O'Dwyer and Comis, {Robert L.}",
year = "2004",
month = "2",
day = "15",
doi = "10.1158/1078-0432.CCR-03-0238",
language = "English (US)",
volume = "10",
pages = "1206--1211",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Evaluating Antiangiogenesis Agents in the Clinic

T2 - The Eastern Cooperative Oncology Group Portfolio of Clinical Trials

AU - Sparano, Joseph A.

AU - Gray, Robert

AU - Giantonio, Bruce

AU - O'Dwyer, Peter

AU - Comis, Robert L.

PY - 2004/2/15

Y1 - 2004/2/15

N2 - Recent evidence indicates that treatment with a humanized monoclonal antibody (bevacizumab) directed at vascular endothelial growth factor improves response and survival in metastatic colorectal cancer when added to standard chemotherapy, validating angiogenesis as a therapeutic target. Investigators from the Eastern Cooperative Oncology Group (ECOG) have initiated a number of Phase III studies that will help further define the role of antiangiogenic agents for the treatment of breast, colon, lung, renal, and head and neck cancer, as well as melanoma and myeloma. The agents being evaluated target various biological functions involved in angiogenesis, including vascular endothelial growth factor (bevacizumab), endothelial cell proliferation (thalidomide, IFN-α), and matrix metalloproteinases (marimastat). These clinical trials include correlative laboratory studies aimed at elucidating how these agents may exert their clinical effects. The portfolio of Eastern Cooperative Oncology Group studies will serve to further define the role of this therapeutic strategy for patients with advanced cancer.

AB - Recent evidence indicates that treatment with a humanized monoclonal antibody (bevacizumab) directed at vascular endothelial growth factor improves response and survival in metastatic colorectal cancer when added to standard chemotherapy, validating angiogenesis as a therapeutic target. Investigators from the Eastern Cooperative Oncology Group (ECOG) have initiated a number of Phase III studies that will help further define the role of antiangiogenic agents for the treatment of breast, colon, lung, renal, and head and neck cancer, as well as melanoma and myeloma. The agents being evaluated target various biological functions involved in angiogenesis, including vascular endothelial growth factor (bevacizumab), endothelial cell proliferation (thalidomide, IFN-α), and matrix metalloproteinases (marimastat). These clinical trials include correlative laboratory studies aimed at elucidating how these agents may exert their clinical effects. The portfolio of Eastern Cooperative Oncology Group studies will serve to further define the role of this therapeutic strategy for patients with advanced cancer.

UR - http://www.scopus.com/inward/record.url?scp=1642321097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642321097&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-03-0238

DO - 10.1158/1078-0432.CCR-03-0238

M3 - Article

VL - 10

SP - 1206

EP - 1211

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -